Metabolic & Cardiometabolic
SGLT1 inhibition decreases postprandial glucose
Strong support Metabolic & Cardiometabolic
RefutedContestedStrong support
consensus score 1.00
📅 Last reviewed: 2026-08-11 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
5 support 0 contradict 0 tested null 0 mixed · 5 sources, 3 independent groups
What the evidence shows
Blocking intestinal SGLT1 delays and blunts glucose absorption, lowering the postprandial rise. Human evidence is consistent and includes a tracer study showing the effect is genuinely absorptive, not renal. The independence caveat is the important one: sotagliflozin IS LX4211 renamed, so the three strongest human trials are one sponsor's drug programme, tagged as a single group.
The evidence (5)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Martinussen C, et al. 2020 · American journal of physiology. Endocrinology and metabolism | RCT | supports | moderate | Randomized controlled crossover, n=10 post-RYGB. Canagliflozin delayed glucose absorption (time-to-peak 3-OMG 50 vs 132 min, p<0.01) and reduced insulin and glucose excursions. |
| Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D 2013 · Clin Ther. 2013 Mar;35(3):273-285.e7 (Epub 2013 Feb 21) | RCT | supports | low | Lexicon LX4211 programme, NCT01441232. 'This 3-treatment, 3-crossover, randomized, open-label study was conducted at a single center' — single-dose LX4211 400 mg, sitagliptin 100 mg, or the combination, in 18 metformin-washed-out T2DM patients ('Clinical: 18 patients were enrolled and treated (mean age, 49 years; 56% male; 89% white)'). The glucose result belongs to the COMBINATION arm against an active comparator, not to LX4211 alone: 'The LX4211 + sitagliptin combination was associated with significantly increased active GLP-1, total GLP-1, and total PYY; with a significant reduction in total GIP; and with a significantly improved blood glucose level, with less insulin, compared with sitagliptin monotherapy.' The abstract's LX4211-monotherapy sentence reports peptides only, not glucose. Direction supports the claim, but the evidence is weak in four ways: no placebo arm, single dose, n=18 open-label single-centre, and the agent is a DUAL SGLT1/SGLT2 inhibitor whose renal route was active and unpartitioned ('In the clinical study, urine was collected to assess urinary glucose excretion'), so the fall is not cleanly attributable to intestinal SGLT1. No effect size, CI or p-value is recoverable — abstract grade only, paper is subscription-locked and not in PMC. All 11 authors are Lexicon Pharmaceuticals staff. Same lexicon-sglt1 group as s23911260 and s31837264. |
| Powell DR, et al. 2020 · The Journal of clinical endocrinology and metabolism | RCT | supports | moderate | Double-blind, randomized, placebo-controlled 3-period crossover (NCT01916863) with dual glucose tracers: '24 healthy participants were randomized to 2 cohorts of 12 participants. Within each cohort, participants were randomly assigned single oral doses of either sotagliflozin 400 mg, canagliflozin 300 mg, or placebo on each of test days 1, 8, and 15.' Direction supports the claim: 'Sotagliflozin delayed and blunted intestinal glucose absorption after meals, resulting in lower PPG and insulin levels, likely due to prolonged local inhibition of intestinal SGLT1 that persisted for >=5 hours after dosing.' Two boundaries the abstract hides. (1) It is redistribution, not reduction: RaO fell over 0-2 h then rose over 2-5 h, 'resulting in insignificant RaO AUC 0-5 hours decreases of 3% for sotagliflozin (P = .31) and 5% for canagliflozin (P = .05)'. (2) Sotagliflozin's own breakfast PPG effect was null - incremental PPG AUC 0-1 h and 0-2 h 'showed insignificant decreases of 25% (P = .20 and P = .14, respectively) for sotagliflozin'; the significant sotagliflozin PPG reductions came at the 4.25-h lunch and, post hoc, the 5.25-h lunch. Mechanism is absorptive, not gastric: 'Neither sotagliflozin nor canagliflozin altered gastric emptying after breakfast'. Insulin fell with it (incremental insulin AUC -26%/-23%/-20% after breakfast, all P < .05), confirmed by concordant C-peptide. Quality moderate, not high: n=24 healthy volunteers, single dose, 'This study was sponsored by Lexicon Pharmaceuticals' with five authors employed by or holding stock options in the sponsor, 'adjustments for multiple comparisons were not performed due to the exploratory nature of the study', and the authors' own verdict that 'the results are hypothesis generating for the effects of sotagliflozin in patients with diabetes.' Independence: same lexicon-sglt1 programme as the other strong human sotagliflozin trials - not a separate replication. |
| Io F, et al. 2019 · European journal of pharmacology | animal | supports | moderate | SGL5213, a gut-restricted SGLT1 inhibitor, improved postprandial hyperglycaemia in STZ-diabetic rats at >=1 mg/kg and increased residual glucose in distal gut, confirming the absorptive mechanism. Rat. |
| Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A 2013 · Clin Ther. 2013 Aug;35(8):1162-1173.e8 (Epub 2013 Jul 31) | RCT | supports | low | Randomized, double-blind, placebo-controlled multiple-dose dose-timing study, n=12 healthy subjects aged 30-51 (NCT01334242). 'Treatment with LX4211 resulted in significant elevation of total and active GLP-1, and PYY while significantly decreasing PPG levels relative to placebo'; 'dosing immediately before breakfast maximized the PD effects of LX4211 on both SGLT1 and SGLT2 inhibition.' Quality low: n=12, all ten authors are Lexicon Pharmaceuticals staff on the sponsor's own molecule, urinary glucose excretion was an explicit endpoint so the renal SGLT2 route was live alongside the intestinal one, and not one effect size, CI or p-value is recoverable (not open access, abstract is the ceiling). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.